Search

Corcept Therapeutics Inc

Закрыт

СекторЗдравоохранение

109.34 -2.43

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

108.84

Макс.

112.91

Ключевые показатели

By Trading Economics

Доход

-130M

-32M

Продажи

-37M

165M

P/E

Средняя по отрасли

260.343

64.641

Прибыль на акцию

-0.3

Рентабельность продаж

-19.26

Сотрудники

730

EBITDA

-55M

-44M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+8.69% upside

Дивиденды

By Acuity

Следующий отчет о доходах

3 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

4.8B

9.8B

Предыдущая цена открытия

111.77

Предыдущая цена закрытия

109.34

Corcept Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 авг. 2026 г., 19:16 UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

3 авг. 2026 г., 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

31 июл. 2026 г., 22:26 UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

30 июл. 2026 г., 23:11 UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

29 июл. 2026 г., 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

28 июл. 2026 г., 19:46 UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

27 июл. 2026 г., 23:46 UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

24 июл. 2026 г., 21:01 UTC

Corcept Therapeutics shares are lower in after-market trading, reflecting broader negative sentiment following earnings reports from major companies like Tesla and Alphabet.

22 июл. 2026 г., 19:51 UTC

Corcept Therapeutics Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

21 июл. 2026 г., 17:06 UTC

Corcept Therapeutics Inc is trading higher today, reflecting broader market trends as regional indices like the Nikkei 225 also show gains.

20 июл. 2026 г., 18:13 UTC

Social Media

Corcept Therapeutics shares are higher today, boosted by FDA approval of Lifyorli and increased trading volume amid heightened investor interest.

Сравнение c конкурентами

Изменение цены

Corcept Therapeutics Inc Прогноз

Целевая цена

By TipRanks

8.69% рост

Прогноз на 12 месяцев

Средняя 122.6 USD  8.69%

Максимум 165 USD

Минимум 50 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Corcept Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

5 ratings

4

Покупка

0

Удержание

1

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat